302 related articles for article (PubMed ID: 35612318)
1. Targeting interleukin-13 receptor α2 (IL-13Rα2) for glioblastoma therapy with surface functionalized nanocarriers.
Liang R; Wu C; Liu S; Zhao W
Drug Deliv; 2022 Dec; 29(1):1620-1630. PubMed ID: 35612318
[TBL] [Abstract][Full Text] [Related]
2. Significance of interleukin-13 receptor alpha 2-targeted glioblastoma therapy.
Thaci B; Brown CE; Binello E; Werbaneth K; Sampath P; Sengupta S
Neuro Oncol; 2014 Oct; 16(10):1304-12. PubMed ID: 24723564
[TBL] [Abstract][Full Text] [Related]
3. Interleukin-13 receptor alpha 2-targeted glioblastoma immunotherapy.
Sengupta S; Thaci B; Crawford AC; Sampath P
Biomed Res Int; 2014; 2014():952128. PubMed ID: 25247196
[TBL] [Abstract][Full Text] [Related]
4. Analysis of the cancer genome atlas (TCGA) database identifies an inverse relationship between interleukin-13 receptor α1 and α2 gene expression and poor prognosis and drug resistance in subjects with glioblastoma multiforme.
Han J; Puri RK
J Neurooncol; 2018 Feb; 136(3):463-474. PubMed ID: 29168083
[TBL] [Abstract][Full Text] [Related]
5. Plasma IL13Rα2 as a novel liquid biopsy biomarker for glioblastoma.
Khristov V; Nesterova D; Trifoi M; Clegg T; Daya A; Barrett T; Tufano E; Shenoy G; Pandya B; Beselia G; Smith N; Mrowczynski O; Zacharia B; Waite K; Lathia J; Barnholtz-Sloan J; Connor J
J Neurooncol; 2022 Dec; 160(3):743-752. PubMed ID: 36436150
[TBL] [Abstract][Full Text] [Related]
6. RGD and interleukin-13 peptide functionalized nanoparticles for enhanced glioblastoma cells and neovasculature dual targeting delivery and elevated tumor penetration.
Gao H; Xiong Y; Zhang S; Yang Z; Cao S; Jiang X
Mol Pharm; 2014 Mar; 11(3):1042-52. PubMed ID: 24521297
[TBL] [Abstract][Full Text] [Related]
7. A novel ligand delivery system to non-invasively visualize and therapeutically exploit the IL13Rα2 tumor-restricted biomarker.
Nguyen V; Conyers JM; Zhu D; Gibo DM; Hantgan RR; Larson SM; Debinski W; Mintz A
Neuro Oncol; 2012 Oct; 14(10):1239-53. PubMed ID: 22952195
[TBL] [Abstract][Full Text] [Related]
8. Construction of IL-13 Receptor α2-Targeting Resveratrol Nanoparticles against Glioblastoma Cells: Therapeutic Efficacy and Molecular Effects.
Lin XM; Shi XX; Xiong L; Nie JH; Ye HS; Du JZ; Liu J
Int J Mol Sci; 2021 Sep; 22(19):. PubMed ID: 34638961
[TBL] [Abstract][Full Text] [Related]
9. Targeting glioblastoma multiforme using a novel fusion protein comprising interleukin-13 and staphylococcal enterotoxin B in vitro.
Gholipour Z; Fooladi AAI; Parivar K; Halabian R
Toxicol In Vitro; 2023 Oct; 92():105651. PubMed ID: 37482138
[TBL] [Abstract][Full Text] [Related]
10. Identification of a novel role of IL-13Rα2 in human Glioblastoma multiforme: interleukin-13 mediates signal transduction through AP-1 pathway.
Bhardwaj R; Suzuki A; Leland P; Joshi BH; Puri RK
J Transl Med; 2018 Dec; 16(1):369. PubMed ID: 30572904
[TBL] [Abstract][Full Text] [Related]
11. An interleukin 13 receptor α 2-specific peptide homes to human Glioblastoma multiforme xenografts.
Pandya H; Gibo DM; Garg S; Kridel S; Debinski W
Neuro Oncol; 2012 Jan; 14(1):6-18. PubMed ID: 21946118
[TBL] [Abstract][Full Text] [Related]
12. T cells redirected to interleukin-13Rα2 with interleukin-13 mutein--chimeric antigen receptors have anti-glioma activity but also recognize interleukin-13Rα1.
Krebs S; Chow KK; Yi Z; Rodriguez-Cruz T; Hegde M; Gerken C; Ahmed N; Gottschalk S
Cytotherapy; 2014 Aug; 16(8):1121-31. PubMed ID: 24841514
[TBL] [Abstract][Full Text] [Related]
13. Transgenic Expression of IL15 Improves Antiglioma Activity of IL13Rα2-CAR T Cells but Results in Antigen Loss Variants.
Krenciute G; Prinzing BL; Yi Z; Wu MF; Liu H; Dotti G; Balyasnikova IV; Gottschalk S
Cancer Immunol Res; 2017 Jul; 5(7):571-581. PubMed ID: 28550091
[TBL] [Abstract][Full Text] [Related]
14. Expression of interleukin-13 receptor alpha2 in glioblastoma multiforme: implications for targeted therapies.
Jarboe JS; Johnson KR; Choi Y; Lonser RR; Park JK
Cancer Res; 2007 Sep; 67(17):7983-6. PubMed ID: 17804706
[TBL] [Abstract][Full Text] [Related]
15. Bioactivity and Safety of IL13Rα2-Redirected Chimeric Antigen Receptor CD8+ T Cells in Patients with Recurrent Glioblastoma.
Brown CE; Badie B; Barish ME; Weng L; Ostberg JR; Chang WC; Naranjo A; Starr R; Wagner J; Wright C; Zhai Y; Bading JR; Ressler JA; Portnow J; D'Apuzzo M; Forman SJ; Jensen MC
Clin Cancer Res; 2015 Sep; 21(18):4062-72. PubMed ID: 26059190
[TBL] [Abstract][Full Text] [Related]
16. Recent Advances in the Therapeutic Strategies of Glioblastoma Multiforme.
Aldoghachi AF; Aldoghachi AF; Breyne K; Ling KH; Cheah PS
Neuroscience; 2022 May; 491():240-270. PubMed ID: 35395355
[TBL] [Abstract][Full Text] [Related]
17.
Gallego L; Ceña V
Expert Opin Drug Deliv; 2020 Nov; 17(11):1541-1554. PubMed ID: 32791861
[TBL] [Abstract][Full Text] [Related]
18. Characterization and Functional Analysis of scFv-based Chimeric Antigen Receptors to Redirect T Cells to IL13Rα2-positive Glioma.
Krenciute G; Krebs S; Torres D; Wu MF; Liu H; Dotti G; Li XN; Lesniak MS; Balyasnikova IV; Gottschalk S
Mol Ther; 2016 Feb; 24(2):354-363. PubMed ID: 26514825
[TBL] [Abstract][Full Text] [Related]
19. Multi-ligand functionalized blood-to-tumor sequential targeting strategies in the field of glioblastoma nanomedicine.
Martins C; Sarmento B
Wiley Interdiscip Rev Nanomed Nanobiotechnol; 2023; 15(5):e1893. PubMed ID: 37186374
[TBL] [Abstract][Full Text] [Related]
20. Interleukin-13 receptor alpha 2 cooperates with EGFRvIII signaling to promote glioblastoma multiforme.
Newman JP; Wang GY; Arima K; Guan SP; Waters MR; Cavenee WK; Pan E; Aliwarga E; Chong ST; Kok CYL; Endaya BB; Habib AA; Horibe T; Ng WH; Ho IAW; Hui KM; Kordula T; Lam PYP
Nat Commun; 2017 Dec; 8(1):1913. PubMed ID: 29203859
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
